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Abstract
Accurate interpretation of gene testing is a key component in customizing patient therapy. Where confirming
evidence for a gene variant is lacking, computational prediction may be employed. A standardized framework,
however, does not yet exist for quantitative evaluation of disease association for uncertain or novel gene variants
in an objective manner. Here, complementary predictors for missense gene variants were incorporated into a
weighted Consensus framework that includes calculated reference intervals from known disease outcomes. Data
visualization for clinical reporting is also discussed.
Background
For appropriate and effective patient treatment, relevant
clinical information should be available to the clinician
on demand. Accurate interpretation of gene test results,
including phenotype association of gene variants, is an
important component in customizing patient therapy.
Recent endeavors such as the NCBI Genetic Testing
Registry, MutaDATABASE, 1000 Genomes and the
Human Variome Project draw attention to this growing
interest in gene variant annotation and clinical interpre-
tation in human disease [1-4]. Ongoing efforts to catalog
human genome variation for many years have led to
authoritative repositories of gene variants, with clear
association to disease phenotype finally beginning to
emerge [5-8].
Rapidly evolving technologies such as SNP chip gen-
ome-wide association studies and next-generation
sequencing have lowered the cost and increased the
speed of genomic analysis, yielding much larger data
sets [9]. Currently, gene variants are being discovered at
an unprecedented pace. One recent report found an
average of 3 million variants per personal genome [10].
Unfortunately, an ever-widening gap exists between this
fast growing collection of genetic variation and practical
clinical interpretation due to a lack of understanding of
the phenotypic consequences (if any) of any given var-
iant. Although the number of genetic testing labora-
tories has remained around 600 over the past several
years, recent data show that clinical testing is currently
available for well over 2,200 different genes or genetic
conditions [11]. As medical records increasingly incor-
porate genetic test information, improved decision sup-
port approaches are needed to provide clinicians with
the preferred course of treatment [12,13]. Furthermore,
for decision support rules to be of value, the clinical
relevance of laboratory information must be well under-
stood [14,15].
Updated recommendations have been proposed from
the American College of Medical Geneticists (ACMG)
on reporting and classification of sequence variants,
including approaches to help determine the clinical sig-
nificance of variants of uncertain significance [16].
These guidelines delineate six interpretative categories
of gene sequence variation, with defined classifications
outlined and the hope of a unified standard terminology
in gene test reporting. For improving interpretation of
unclassified genetic variants, definitions and terminology
have also been recommended by the International
Agency for Research on Cancer (IARC), part of the
World Health Organization [17].
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Despite these recommendations, however, for genetic
laboratories to unify and standardize terminology and
classification of gene variant test reporting, various
terms such as ‘deleterious’, ‘mutation’, ‘pathogenic’ or
‘causative of disease’ are still being used [18]. In a simi-
lar vein, test results such as ‘indeterminate’, ‘unknown’,
‘uncertain’, ‘unclassified’ and ‘undetermined’ make it dif-
ficult to interpret the significance of a gene test result.
Further compounding this issue, word modifiers such as
‘likely’, ‘suspected’, ‘predicted’ and ‘mild’, ‘moderate’ or
‘severe’ sometimes also accompany variant classification.
Of this environment, one recent study perceptively
noted, ‘The outcome of this inconsistency for clinicians
and patients in such cases is uninformative; unhelpful at
best and, at worst, open to misinterpretation’ [19]. In
this light, the prevailing question becomes how to best
help clinicians faced with decisions around gene variants
of uncertain significance.
A brief review of the literature indicates that gene test
reports of variants of uncertain significance range
widely. One laboratory site reported that from 30% to
50% of sequence changes reported for BRCA1 and
BRCA2, respectively, were reported as variants of uncer-
tain significance [20]. Similarly, analysis of a second
laboratory revealed that a physician who orders BRCA1
and BRCA2 testing had an equal likelihood (13%) of
receiving an uncertain variant result as seeing a test
report containing a known pathogenic mutation [21].
More recent data indicate that identification of variants
of uncertain significance has continued to decline to
approximately 5% of BRCA tests performed - a testa-
ment to the importance of maintaining and updating
variant databases [22].
Another well-known example is hereditary nonpolypo-
sis colorectal cancer syndrome, where according to the
US Preventive Services Task Force and others, a clini-
cian may expect some 13% to 31% of tests reports to
say mutation of unknown significance (uncertain var-
iant) [23,24]. An uncertain variant indicates that the risk
of cancer is not fully defined and patient treatment is
then based on personal and family history of cancer.
Clinicians may be further frustrated when the chance of
receiving a test report containing an uncertain variant is
even higher for individuals from under-represented eth-
nic groups due to insufficient data on common poly-
morphisms from that population [25]. Additionally,
newly identified variants from known genes present a
greater challenge for interpretation of sequence-based
results because they lack traditional confirming evidence
of disease association [26].
Clinician frustration and obstacles to wide adoption of
proposed guidelines may be two-fold. First, the lack of
any quantitative metric or standardized scale for evalua-
tion of novel or uncertain gene variants makes each
difficult test result interpretation subjective to location
and expertise at hand. A second and closely related
challenge is the lack of an objective and standardized
framework or context to make that metric meaningful.
This quantitative metric and framework for evaluation
become especially critical for interpretation of novel and
uncertain gene variants where there is the obvious lack
of existing evidence, such as family history, pedigree
trios or sib pairs, confirming literature reports, bench
assay biochemical evidence or colleague consensus of
disease association.
In an effort to increase the transparency of providing
gene variant evidence in test reporting to the clinical
setting, we here present an implementation of our
recently reported gene-specific predictor (Primary
Sequence Amino Acid Properties (PSAAP)) into a stan-
dardized framework, in which results are systematically
compared with those of other computer-based predic-
tion methods for missense variants. Finally, with analogy
to conventional laboratory testing, this Consensus
model of complementary predictors also calculates gene
variant ‘reference intervals’ using known disease out-
comes. Examples of visualization are also explored for
augmenting diagnostic decision making.
Materials and methods
Several clinically curated disease sets of gene variants
with known pathogenicity are publicly available at
ARUP Scientific Resource for Research and Education
[27]. Each database relies on both medical and molecu-
lar expertise, and uniquely displays mutation and clinical
information together. All sequence variants are verified
for genomic position within a given reference gene and
named following standard Human Genome Variation
Society (HGVS) nomenclature [28]. Archived non-
synonymous substitution variants were accessed from
the RET proto-oncogene database in January 2012 [29].
Established prediction algorithms were chosen with
various and complementary methodologies, such as
amino acid substitution penalties, structural disruption,
sequence homology (ortholog conservation) and neural
nets. Mutation prediction was then performed for
known benign (n = 46), known pathogenic (n = 51) and
uncertain variants (n = 45) using our gene-specific
PSAAP algorithm, and established algorithms MutPred
[30], PMut [31], PolyPhen [32] and SIFT [33] as pre-
viously described [34,35]. Prediction analysis was per-
formed during December 2011 and January 2012 using
the respective default settings for each algorithm.
Descriptive statistics such as mean, median, standard
deviation, minimum and maximum were calculated for
the numerical output from all five prediction algorithms.
Normality of the variable distributions was assessed
using the Shapiro-Wilk test, where the null hypothesis
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assumes that the data are normally distributed and
interpreted by a Pvalue greater than the chosen alpha
level means a normal distribution was found. Next, for
predictor variables that were found to be statistically
and significantly in a non-normal distribution, Spearman
correlation coefficients were calculated to evaluate cor-
relation between predictors. To account for correlations
between predictor variables, and to establish a parsimo-
nious subset of predictors, principle components were
calculated using factor analysis. Finally, the resulting sig-
nificant principle components were used to develop a
set of linearly independent predictor values. The
weighted average of the five predictor scores was then
calculated as the ‘Consensus’ score (Table 1). All calcu-
lations were performed using SAS software, version 9.1
(SAS Institute Inc., Cary, NC, USA).
Next, with analogy to calculating analyte reference
intervals for age or gender in traditional laboratory test-
ing, a ‘reference range’ of Consensus scores for RET
gene variants with known disease outcome was calcu-
lated using EP Evaluator 8 (Data Innovations, South
Burlington, VT, USA). A nonparametric reference inter-
val was used for benign (n = 46) and pathogenic (n =
51) with 95% confidence intervals (CI) for the lower and
upper bounds (Table 2). The confidence ratio of the
reference interval was also calculated. Due to the reci-
procal nature of the SIFT score (where a lower predic-
tion value corresponds to more ‘pathogenic’), 1-SIFT
was used. All predictor scores were normalized to a
scale of 0 to 100.
Finally, in order to better evaluate the performance of
the Consensus framework, a comparison to Condel [36]
and SNPs&GO [37] was performed. Further, five-fold
cross-validation was implemented and performed using
the Weka software package [38]. Cross-validation area
under the curve (AUC) was calculated and plotted using
R (v2.14.2) and the ROCR package as shown in Figure
1. We also retrospectively removed seven RET gene var-
iants with known disease association (two benign, five
pathogenic) from training and test sets and repeated
analysis using the proposed model framework. Disease
outcome predictions and Consensus scoring were evalu-
ated for each of these variants.
Appropriate graphical summary of diagnostic informa-
tion, including predictive algorithms is key for visualiza-
tion and interpretation of any results generated [39]. We
have loosely based the Consensus display on output
from representative algorithms such as Scolioscore and
FibroTest, where sample test reports are shown in Fig-
ures S1 and S2 in Additional file 1, respectively [40,41].
Finally, the use of radar (radial) plots is well documen-
ted and serves to preserve the contribution of each pre-
dictor in the weighted Consensus sum [42,43].
Results and discussion
Prediction results (numerical output) from the five algo-
rithms were obtained for RET gene variants with known
disease association of benign (Table S1 in Additional file
2) and pathogenic (Table S2 in Additional file 2). Pre-
dictor results for RET gene variants with no reported
Table 1 Working example of calculating the weighted Consensus score
Predictor Prin1 Prin2 Prin3
PSAAP 0.56 0.25 0.25
MutPred 0.62 0.14 0.22
PMUT 0.46 0.36 -0.06
PolyPhen -0.27 0.40 0.77
1-SIFT 0.06 0.79 -0.54
Varianta PSAPPb MutPredc PMUTd PolyPhene SIFTf
Pathogenic
C609Y 0.85 0.90 0.98 0.97 0.00
Vector1 = 0.85 × 0.56 +0.90 × 0.62 +0.98 × 0.46 +0.97 × -0.27 +(1-0.00) × 0.06 = 1.283
Vector2 = 0.85 × 0.25 +0.90 × 0.14 +0.98 × 0.36 +0.97 × 0.40 +(1-0.00) × 0.79 = 1.869
Vector3 = 0.85 × 0.25 +0.90 × 0.22 +0.98 × -0.06 +0.97 × 0.77 +(1-0.00) × -0.54 = 0.559
Weighted sum (× 100) = 371.1
Benign
V376A 0.07 0.13 0.19 0.04 0.60
Vector1 = 0.07 × 0.56 +0.13 × 0.62 +0.19 × 0.46 +0.04 × -0.27 +(1-0.60) × 0.06 = 0.220
Vector2 = 0.07 × 0.25 +0.13 × 0.14 +0.19 × 0.36 +0.04 × 0.40 +(1-0.60) × 0.79 = 0.436
Vector3 = 0.07 × 0.25 +0.13 × 0.22 +0.19 × -0.06 +0.04 × 0.77 +(1-0.60) × -0.54 = - 0.150
Weighted sum (× 100) = 50.6
aRET_HUMAN (UniProt #P07949) used as reference amino acid sequence. bPrimary Sequence Amino Acid Properties (PSAAP) algorithm, gene-specific trained.
cAnalyzed with default settings at [57]. dAnalyzed with default settings at [58]. eAnalyzed with default settings at [59]. fAnalyzed with default settings at [60].
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disease association (uncertain) are summarized in Table
S3 in Additional file 2. Results of correlation between
predictors and significance of correlation are summar-
ized in Table S4 in Additional file 2. Substantial correla-
tion was seen in at least three of the five predictors
(MutPred, PSAAP, and PMut). This significant correla-
tion between variables indicates that a simple linear sum
of predictors could not be used to combine the predic-
tion scores. A weighted predictor sum (Consensus)
required linear transformation of predictor outputs as
determined by factors analysis.
Factor analysis was performed using principal compo-
nents to determine weights of association between the
five different predictors. More specifically, a set of eigen-
vectors was applied to weight each predictor accordingly
by eigenvalues from principal components, with > 80%
cumulative variance explained reached using only the
first three eigenvalues. Factor analysis and cumulative
percent variance explained by eigenvectors is detailed in
Figure S3 in Additional file 1. PRINCOMP results and
eigenvalues are summarized in Table S5 in Additional
file 2.
A working example of the Consensus score for both a
known benign and known pathogenic RET gene variant
is detailed in Table 1, where each predictor sum is
weighted and scaled to 100. Using this same method to
sum each of the five predictors for each gene variant,
we then computed reference range metrics for benign
and pathogenic variants for the RET proto-oncogene.
Benign variants ranged from 85 to 243, while pathogenic
variants ranged from 305 to 462. Confidence ratios for
the calculated reference intervals were 0.09 and 0.16,
respectively. The RET gene variant Consensus reference
intervals are summarized using scatter plot distribution
of scores for benign and pathogenic as displayed in Fig-
ure 2. Further demonstrating the utility of a reference
interval metric for gene variants, the distribution of
Consensus scores for prediction of RET uncertain gene
variants shows approximate groupings into reference
interval ranges also plotted in Figure 2.
In combination, the overall Consensus score may aug-
ment the rare instance that a gene-specific prediction
does not outperform the existing tools. Some advantage
of Consensus over existing predictors was demonstrated
by performing a comparison with recently popular tools
such as Condel and SNPS&GO [36,37]. The comparison
demonstrated a surprisingly accurate agreement among
gene variants (n = 121) with known pathogenic disease
outcomes, where Condel showed 99.2% agreement and
SNPs&GO 93.4% agreement. For variants with known
benign outcomes (n = 67), however, Condel scored only
17.1% agreement, while SNPs&GO was slightly better
with 28.6% agreement. Results for five-fold cross-valida-
tion showed acceptable reproducibility with 97.9% preci-
sion and 93.5% recall, yet a trend of overcalling disease
causing predictions was readily apparent, as seen in Fig-
ure 1.
Further, to approximate the longitudinal and moving
target of phenotype curation, Consensus performance
was also retrospectively confirmed by removing seven
RET gene variants with known disease association where
originally they were classified as variants of uncertain
significance. After excluding these seven variants from
the gene-specific training set, analysis using the Consen-
sus framework was repeated. Due to the lack of a repre-
sentative variant in the training data, PSAAP only called
disease association correctly for five out of seven var-
iants. In combination, however, the Consensus score
correctly predicted the sixth variant. Closer inspection
showed the remaining seventh variant was a nucleotide-
level ‘silent’ polymorphism (no amino acid change),
which may have been recognized by splice effect predic-
tion software.
Finally, one common graphing display technique to
preserve contribution of each variable (predictor) is the
use of radial plots (also known as radar or spider plots).
RET Consensus scoring results (unweighted) for the
pathogenic variant C609Y and benign variant V376A are
shown using radar plots in Figure 3. For augmenting
clinical decision making, a more comprehensive display
for Consensus scoring is shown in Figure 4, which
incorporates algorithm output, predictor calls, weighted
sum and colorimetric scale.
Currently, there is no widely accepted computational
predictor in clinical use for evaluating uncertain gene
variants. Furthermore, a lack of standardized framework
and quantitative metric for evaluation of disease associa-
tion of novel and uncertain variants remains an obstacle
to widespread implementation of proposed guidelines
and definitions of gene test reporting. The analogy of
conventional laboratory analyte testing with established
cutoffs and reference intervals may serve as a pattern
for gene variant testing. In this regard, we have devel-
oped a standardized framework and metric for evalua-
tion of uncertain gene variants, with the idea that rather
than giving a clinician a ‘black box’ interpretation of
Table 2 Consensus score reference intervals for RET gene variants
Disease outcome N Lower limit value 95% CI Upper limit value 95% CI Confidence ratio
Benign 46 85 < 76 to 98 243 231 to > 255 > 0.09
Pathogenic 51 305 < 287 to 319 462 458 to > 470 > 0.16
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Figure 1 Cross-validation for individual predictor performance. (a) Calculated area under the curve (AUC) of RET predictor cross-validation
results for individual predictor performance, including PSAAP (0.971), MutPred (0.845), PMut (0.698), PolyPhen-2 (0.555) and SIFT (0.630). (b) AUC
results for the gene-specific predictor PSAAP (0.971), the combined predictor Consensus (0.998) and ConDel (0.587) with overcall of ‘pathogenic’
results for actual benign variants.
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uncertain gene variants, the evidence and decision-mak-
ing is transparent to clinicians so they can use this in
consultation with the patient to make treatment
decisions.
It is likely that providing this type of information will
impact clinical decision making. While critics may argue
that relying solely on a computational framework might
‘mislead’ clinicians in that we do not have the best evi-
dence (that is, a true known genotype-phenotype corre-
lation), the reality is that clinicians still have to make
treatment decisions based on any ‘uncertain significance’
result. We propose that increasing the transparency of
gene test evidence and interpretation would only help
the clinician as compared to a situation where results
that are on the border of benign and those on the
border of pathogenic are treated the same. As Consen-
sus is implemented into a laboratory setting, coordina-
tion with a clinical site to test how clinicians use the
information would be an important and necessary fol-
low-up study.
The lack of a widely accepted standard for computa-
tional predictors in a clinical setting remains a serious
obstacle in the diagnostic utility of these algorithms.
Gene-specific prediction algorithms have been shown to
be an improvement over existing generalized prediction
tools, where a larger data set ‘n’ for training algorithms
may not compensate for lower quality of phenotype infor-
mation. Examples of this gene-disease-specific focus using
computational prediction have recently been shown for
hypertrophic cardiomyopathy and in the RET proto-onco-
gene [35,44]. We have recently summarized similar efforts
in gene-specific prediction for an authoritative 20 gene-
disease data set showing similar improved prediction [45].
Focusing prediction algorithms on authoritative and speci-
fic gene-disease settings may aid to bridge this acceptance
Figure 2 Gene-specific reference intervals. Scatter plot
visualization of unweighted Consensus scores for RET gene variants,
including known benign, known pathogenic disease association and
gene variants of uncertain significance, demonstrating the utility of




























Figure 3 Plotting individual predictor contribution. Using radar
plots for Consensus scoring preserves the contribution of each
predictor to the total sum. (a) Consensus score plot of 470 (85, 90,
98, 97, 100) for the pathogenic gene variant C609Y. (b) Consensus
output of 103 (7, 13, 19, 4, 60) for a benign variant V376A. Individual
predictor scores are shown here as unweighted.
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gap and shed additional light on clinical interpretation of
uncertain gene variants. With ongoing efforts to amass
gene variation in human disease, newly emerging ‘authori-
tative’ or ‘diagnostic grade’ clinically curated gene variant
archives should be leveraged for training and testing
machine learning classification tools.
Medical geneticists rely on patient history, family seg-






















Predictor Raw Call Consensus Weights
PSAAP 0.26 benign 27.4 PSAAP(0.563+0.245+0.247)*100
MutPred 0.20 benign 19.1 MutPred(0.622+0.141+0.219)*100 
PMUT 0.66 neutral 50.1 PMUT(0.464+0.357-0.064)*100 
PolyPhen 0.00 benign 0.0 PolyPhen(-0.237+0.401+0.77)*100 
SIFT 0.66 tolerated 10.9 1-SIFT(0.063+0.793-0.536)*100
107.5
RET – C634R 
Predictor Raw Call Consensus Weights
PSAAP 0.85 pathogenic  89.7 PSAAP(0.563+0.245+0.247)*100
MutPred 0.79 pathogenic  77.6 MutPred(0.622+0.141+0.219)*100 
PMUT 0.88 pathological  66.6 PMUT(0.464+0.357-0.064)*100 
PolyPhen 1.00 prob damaging 93.4 PolyPhen(-0.237+0.401+0.77)*100 
SIFT 0.02 affects function 31.4 1-SIFT(0.063+0.793-0.536)*100
358.6
Figure 4 Consensus score display. (a, b) Visualization of the five-predictor Consensus model, including algorithm output, predictor calls, weighting
sum and colorimetric scale for pathogenic gene variant C634R (a), scoring 359, and benign variant G691S (b) with a Consensus score of 108.
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informed of the phenotypic consequences of a given
gene variant. In addition, well established computer pre-
diction tools are often employed [16,46]. One recent
report (Condel) details combining various algorithms
into a single score to assess ‘deleteriousness’ in nonsy-
nonymous (missense) variants [36]. Supporting compu-
tational methods may serve to replicate this same
mental process of gathering evidence from complemen-
tary sources, assessing agreement of the evidence and
summarizing this evidence into a clinical context for
interpretation of the gene variant finding [47].
For scenarios lacking conventional gene variant evi-
dence, the five specific predictors used for Consensus
were carefully chosen due to the varied computational
approach of each algorithm. Analysis of variance shows
the majority of the weighted average stems from three
of the five predictors (PSAAP, MutPred and PMut).
This may be indicative of the unique and varied
approach of the three predictors. SIFT and PolyPhen
were also included in the Consensus score for a ‘wisdom
of the crowd’ historical context due to the fact that
many laboratories may already have these prediction
algorithms in use.
One limitation of this methodology is the fact that
although several popular gene variants collections are
ongoing (dbSNP has recently passed the 12 million
unique human gene variant milestone), a relatively small
number of clinically curated and authoritative gene-dis-
ease collections exist as used for diagnostic purposes.
Fortunately, this number will likely continue to expand
over time, not diminish, as gene-disease associations are
better understood and personalized patient treatments
advance. Another limitation is that mutation archives
often have an unbalanced proportion of disease-causing
gene variants, and appropriate machine learning techni-
ques must be used to compensate for uneven training
and test data. In addition, a given gene variant may not
only result in a missense change as being evaluated
here, but may also impact splicing and translation of a
gene product and thus be deleterious even when an
apparently benign effect is expected.
Perhaps the most important limitation to acknowl-
edge is how can we know whether a prediction for a
gene variant of uncertain significance is truly correct?
The honest response is likely ‘we can not’. While only
the passage of time may confirm the accuracy of a
computational prediction, an important point not to
dismiss is - would this approach (or similar) likely
lead to better or worse decision-making by providers?
One recent article points to the importance of careful
curation in locus-specific databases [48] and these col-
lections should be leveraged for algorithm improve-
ments. There may also be analogous situations in
other existing laboratory tests, where, for example,
anatomic pathology may yield some ideas that clini-
cians rely on for decision-making. The pathology
report contains all information, not just the ‘interpre-
tation’. Importantly, this would imply that more infor-
mation (not less) is appropriate for clinician decision-
making [19,49].
Another key issue is that disease classification of
gene variants evolves over time as new knowledge
becomes available. We note that this is a problem
whether one uses this proposed framework or the sta-
tus quo system for dealing with gene test results of
uncertain significance. At present, there is no way to
communicate new variant knowledge effectively
between gene test laboratories and clinicians. Thus, a
standardized framework would allow for consistent
and objective data provenance for longitudinal tracking
of both variants and patient results, where notifying
interested parties in updated variant classification and
disease association would be more feasible. We also
note that development of this framework now using
monogenic diseases may allow increased understanding
that could eventually be applied to multi-gene panel or
whole genome approaches.
There may be some perceived liability of a laboratory
that would report using this augmented methodology as
compared to existing gene test reporting approaches.
Although correlation of genotype-phenotype offers ther-
apeutic options that would otherwise remain hidden and
may lead to disease-specific, mutation-guided manage-
ment strategies, appropriate caution is justified when
clinicians are asked to trust computational outcomes for
determining patient care [50]. On the other hand, when
results are reported to clinicians and patients as variants
of unknown significance, it may take years for sufficient
molecular or family evidence to be confirmed for the
laboratory to make a final determination. Interpretation
of gene test results that are unclear or uncertain may be
troubling for patients, and must have some effect (good
or bad) on how clinicians manage these patients [51].
Transparent communication of summarized gene var-
iant evidence and continued interaction between clini-
cians and laboratorians to refine mutation-specific
clinical classification is imperative to optimal patient
care. Recent examples of this importance have been
detailed in newborn screening and case studies from
cardiovascular genetics [52,53].
Conclusions
The vision of personalized medicine invokes an image of
all relevant information being available to clinicians on
demand. Proper interpretation of gene test results is one
key area in customizing patient therapy [54,55]. Gene
variants are currently being identified at a tremendous
pace. While many of these sequence changes may be
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considered as normal population allele variants, some
percentage will certainly have disease association. Gene
variants may be best leveraged for clinical utility by
focusing on specific gene-disease areas. In concert,
clinicians and diagnostic laboratories are the best source
of authoritative gene variant annotation. Ranking agree-
ment through the use of a weighted Consensus metric
of predicted pathogenicity across several complementary
(b)
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Figure 5 Protein view with Consensus scoring. (a, b) Proposed visualization of Consensus scoring using known gene variants plotted on the
RET_HUMAN (UniProt #P07949) protein (image courtesy of the Human Protein Reference Database [56]) and weighted algorithm output with
radar plots to summarize predictor evidence for pathogenic gene variant C634R (a), scoring 359, and benign variant G691S (b) with a Consensus
score of 108.
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algorithms may provide a level of clinical confidence in
computational classifiers.
A proposed visual for augmenting the gene test report
of an uncertain gene variant using known benign and
pathogenic gene variants mapped onto a schematic of
the RET protein is displayed in Figure 5. The protein
diagram image is courtesy of the Human Protein Refer-
ence Database [56]. The variant being evaluated is
denoted by ‘X’ along the length of the protein and Con-
sensus scoring of the variant is detailed using both the
reference intervals with colorimetric scale and a radial
chart to show the contribution of each predictor.
Ongoing efforts include expanding the Consensus scor-
ing framework and phenotype reference intervals to
additional genes and diseases. Future efforts will be
necessary to incorporate algorithm layers for nucleotide-
level prediction and functional protein motifs.
Additional material
Additional file 1: Additional figures. Figures S1 and S2: test results
from representative algorithms such as Scolioscore and FibroTest. Figure
S3: analysis of variance explained as determined using principal
components. (A) Scree plot of descending eigenvalues displaying the
five principal components corresponding to the combined predictor
algorithms. (B) Percent variance explained corresponding to the
proportion of cumulative input of five combined predictors.
Additional file 2: Additional tables. Table S1: five predictor results for
benign RET gene variants. Table S2: five predictor results for pathogenic
RET gene variants. Table S3: five predictor results for uncertain RET gene
variants. Table S4: descriptive statistics, correlation of predictors and
significance for RET gene variants with known disease association. Table
S5: principal components and eigenvalues of predictor scores from RET
gene variants with known disease association.
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